Literature DB >> 29926352

Stability of the ABCD1 Protein with a Missense Mutation: A Novel Approach to Finding Therapeutic Compounds for X-Linked Adrenoleukodystrophy.

Masashi Morita1, Shun Matsumoto2, Airi Sato2, Kengo Inoue2, Dzmitry G Kostsin2,3,4, Kozue Yamazaki2, Kosuke Kawaguchi2, Nobuyuki Shimozawa5, Stephan Kemp6, Ronald J Wanders6, Hirotatsu Kojima7, Takayoshi Okabe7, Tsuneo Imanaka2,8.   

Abstract

Mutations in the ABCD1 gene that encodes peroxisomal ABCD1 protein cause X-linked adrenoleukodystrophy (X-ALD), a rare neurodegenerative disorder. More than 70% of the patient fibroblasts with this missense mutation display either a lack or reduction of the ABCD1 protein because of posttranslational degradation. In this study, we analyzed the stability of the missense mutant ABCD1 proteins (p.A616T, p.R617H, and p.R660W) in X-ALD fibroblasts and found that the mutant ABCD1 protein p.A616T has the capacity to recover its function by incubating at low temperature. In the case of such a mutation, chemical compounds that stabilize mutant ABCD1 proteins could be therapeutic candidates. Here, we prepared CHO cell lines stably expressing ABCD1 proteins with a missense mutation in fusion with green fluorescent protein (GFP) at the C-terminal. The stability of each mutant ABCD1-GFP in CHO cells was similar to the corresponding mutant ABCD1 protein in X-ALD fibroblasts. Furthermore, it is of interest that the GFP at the C-terminal was degraded together with the mutant ABCD1 protein. These findings prompted us to use CHO cells expressing mutant ABCD1-GFP for a screening of chemical compounds that can stabilize the mutant ABCD1 protein. We established a fluorescence-based assay method for the screening of chemical libraries in an effort to find compounds that stabilize mutant ABCD1 proteins. The work presented here provides a novel approach to finding therapeutic compounds for X-ALD patients with missense mutations.

Entities:  

Keywords:  ABCD1; Bortezomib; Green fluorescent protein; Missense mutation; X-linked adrenoleukodystrophy

Year:  2018        PMID: 29926352      PMCID: PMC6323035          DOI: 10.1007/8904_2018_118

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  23 in total

1.  Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.

Authors:  Anu R Sawkar; Martina Schmitz; Klaus-Peter Zimmer; David Reczek; Tim Edmunds; William E Balch; Jeffery W Kelly
Journal:  ACS Chem Biol       Date:  2006-05-23       Impact factor: 5.100

Review 2.  Chemical and pharmacological chaperones as new therapeutic agents.

Authors:  Tip W Loo; David M Clarke
Journal:  Expert Rev Mol Med       Date:  2007-06-28       Impact factor: 5.600

3.  Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.

Authors:  Heidi M Sampson; Renaud Robert; Jie Liao; Elizabeth Matthes; Graeme W Carlile; John W Hanrahan; David Y Thomas
Journal:  Chem Biol       Date:  2011-02-25

4.  A Novel Double Mutation in the ABCD1 Gene in a Patient with X-linked Adrenoleukodystrophy: Analysis of the Stability and Function of the Mutant ABCD1 Protein.

Authors:  Masashi Morita; Junpei Kobayashi; Kozue Yamazaki; Kosuke Kawaguchi; Ayako Honda; Kenji Sugai; Nobuyuki Shimozawa; Reiji Koide; Tsuneo Imanaka
Journal:  JIMD Rep       Date:  2013-02-12

5.  Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.

Authors:  L Bezman; A B Moser; G V Raymond; P Rinaldo; P A Watkins; K D Smith; N E Kass; H W Moser
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

Review 6.  Novel pharmacological strategies to treat cystic fibrosis.

Authors:  John W Hanrahan; Heidi M Sampson; David Y Thomas
Journal:  Trends Pharmacol Sci       Date:  2013-02       Impact factor: 14.819

Review 7.  Rescue of folding defects in ABC transporters using pharmacological chaperones.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

8.  Benzbromarone stabilizes ΔF508 CFTR at the cell surface.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochemistry       Date:  2011-05-03       Impact factor: 3.162

9.  Ouabain Mimics Low Temperature Rescue of F508del-CFTR in Cystic Fibrosis Epithelial Cells.

Authors:  Donglei Zhang; Fabiana Ciciriello; Suzana M Anjos; Annamaria Carissimo; Jie Liao; Graeme W Carlile; Haouaria Balghi; Renaud Robert; Alberto Luini; John W Hanrahan; David Y Thomas
Journal:  Front Pharmacol       Date:  2012-10-04       Impact factor: 5.810

10.  Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors.

Authors:  Martina Wilke; Alice Bot; Huub Jorna; Bob J Scholte; Hugo R de Jonge
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more
  2 in total

Review 1.  Disorders of FZ-CRD; insights towards FZ-CRD folding and therapeutic landscape.

Authors:  Reham M Milhem; Bassam R Ali
Journal:  Mol Med       Date:  2019-12-31       Impact factor: 6.354

Review 2.  Aberrant DNA Methylation of ABC Transporters in Cancer.

Authors:  Katja Zappe; Margit Cichna-Markl
Journal:  Cells       Date:  2020-10-13       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.